BioSpace News Archive

Metagenomi, a metagenomics powered gene editing company, today announced the appointment of biotech industry veteran, Jian Irish, Ph.D. as Chief Operating Officer

Nascent Biotech, Inc. (OTCQB:NBIO) , a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce that the Company has officially opened its Phase I trial to evaluate Pritumumab (PTB), the Companys lead Monoclonal Antibody (Mab) therapeutic asset

Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, announced the grant of inducement awards to 12 new employees.

Precision oncology company Lucence announced today a partnership with Waseda University in Japan to develop a novel high-speed liquid biopsy laser-based imaging platform for early cancer detection

Know Labs, Inc., an emerging leader in non-invasive medical diagnostics, through its proprietary electromagnetic energy technology platforms, today shares with the public preliminary study results from Texas Biomedical Research Institute (Texas Biomed) indicating the Particle bulb’s ability to inactivate SARS-CoV-2, the virus that causes COVID-19.

Kebotix, a Cambridge-based technology platform company for new chemicals and materials, announced SIT Capital as a major investor in its Series A funding.

Hutchison China MediTech Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) today announces that it has reached an agreement with GL Mountrose Investment Two Limited, a company controlled and managed by GL Capital Group (“GL Capital”), to sell its entire indirect interest in Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited (“HBYS”),

The agreement focuses on supporting the Company’s reach across the United States and Global marketplace business community along with extending policy advisory services in the U.S.

This will complement the engagement with the U.S. FDA’s Center for Devices & Radiological Health Payor Communication Task Force.

- Exacis has generated NK cells from iPSCs engineered using mRNA gene-editing technology to resist rejection by the patient’s immune system - ExaNK™ cells show superior tumor cell-killing activity and cytokine production compared to peripheral blood-derived NK cells